Fallopian Tube Cancer - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Fallopian Tube Cancer - Pipeline Review, H2 2018’, provides an overview of the Fallopian Tube Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer

- The report reviews pipeline therapeutics for Fallopian Tube Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Fallopian Tube Cancer therapeutics and enlists all their major and minor projects

- The report assesses Fallopian Tube Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Fallopian Tube Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Fallopian Tube Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Advenchen Laboratories LLC

AiVita Biomedical Inc

Aldeyra Therapeutics Inc

Altor BioScience Corp

Amgen Inc

Arrien Pharmaceuticals LLC

Astellas Pharma Inc

Astex Pharmaceuticals Inc ...

AbbVie Inc

Advenchen Laboratories LLC

AiVita Biomedical Inc

Aldeyra Therapeutics Inc

Altor BioScience Corp

Amgen Inc

Arrien Pharmaceuticals LLC

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Bayer AG

BeiGene Ltd

Biocon Ltd

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Celgene Corp

Celldex Therapeutics Inc

Celsion Corp

Celyad SA

Clovis Oncology Inc

Corcept Therapeutics Inc

Cotinga Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Eisai Co Ltd

Eli Lilly and Co

EpiThany Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Forty Seven Inc

Gene Techno Science Co Ltd

Genmab A/S

GlaxoSmithKline Plc

Gradalis Inc

Immune Design Corp

ImmunoGen Inc

IMV Inc

Innate Pharma SA

InSight Biopharmaceuticals Ltd

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Kazia Therapeutics Ltd

MabVax Therapeutics Holdings Inc

Mateon Therapeutics Inc

MaxCyte Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Mersana Therapeutics Inc

Millennium Pharmaceuticals Inc

Morphotek Inc

Mycenax Biotech Inc

NewLink Genetics Corp

Novartis AG

NuCana Plc

Oasmia Pharmaceutical AB

OBI Pharma Inc

Omnitura Therapeutics Inc

Oncobiologics Inc

Oncolix Inc

Oncolytics Biotech Inc

OncoMed Pharmaceuticals Inc

Ono Pharmaceutical Co Ltd

Pfizer Inc

Pharma Mar SA

Plexxikon Inc

Prescient Therapeutics Ltd

Protheragen Inc

PsiOxus Therapeutics Ltd

PTC Therapeutics Inc

Regeneron Pharmaceuticals Inc

Rgenix Inc

Rigel Pharmaceuticals Inc

Samyang Holdings Corp

Sanofi

Sanofi Pasteur SA

SELLAS Life Sciences Group Inc

Sotio AS

Sun Pharma Advanced Research Company Ltd

Syndax Pharmaceuticals Inc

Synermore Biologics Co Ltd

TESARO Inc

Tyrogenex Inc (Inactive)

Vascular Biogenics Ltd

Verastem Inc

Vyriad Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Fallopian Tube Cancer – Overview 7

Fallopian Tube Cancer – Therapeutics Development 8

Fallopian Tube Cancer – Therapeutics Assessment ...

Table of Contents

Table of Contents 2

Introduction 6

Fallopian Tube Cancer – Overview 7

Fallopian Tube Cancer – Therapeutics Development 8

Fallopian Tube Cancer – Therapeutics Assessment 25

Fallopian Tube Cancer – Companies Involved in Therapeutics Development 41

Fallopian Tube Cancer – Drug Profiles 85

Fallopian Tube Cancer – Dormant Projects 1070

Fallopian Tube Cancer – Discontinued Products 1074

Fallopian Tube Cancer – Product Development Milestones 1075

Appendix 1086

List of Tables

List of Tables

Number of Products under Development for Fallopian Tube Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Tables

Number of Products under Development for Fallopian Tube Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Fallopian Tube Cancer – Pipeline by AbbVie Inc, H2 2018

Fallopian Tube Cancer – Pipeline by Advenchen Laboratories LLC, H2 2018

Fallopian Tube Cancer – Pipeline by AiVita Biomedical Inc, H2 2018

Fallopian Tube Cancer – Pipeline by Aldeyra Therapeutics Inc, H2 2018

Fallopian Tube Cancer – Pipeline by Altor BioScience Corp, H2 2018

Fallopian Tube Cancer – Pipeline by Amgen Inc, H2 2018

Fallopian Tube Cancer – Pipeline by Arrien Pharmaceuticals LLC, H2 2018

Fallopian Tube Cancer – Pipeline by Astellas Pharma Inc, H2 2018

Fallopian Tube Cancer – Pipeline by Astex Pharmaceuticals Inc, H2 2018

Fallopian Tube Cancer – Pipeline by AstraZeneca Plc, H2 2018

Fallopian Tube Cancer – Pipeline by Atara Biotherapeutics Inc, H2 2018

Fallopian Tube Cancer – Pipeline by Bayer AG, H2 2018

Fallopian Tube Cancer – Pipeline by BeiGene Ltd, H2 2018

Fallopian Tube Cancer – Pipeline by Biocon Ltd, H2 2018

Fallopian Tube Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2018

Fallopian Tube Cancer – Pipeline by Boston Biomedical Inc, H2 2018

Fallopian Tube Cancer – Pipeline by Bristol-Myers Squibb Co, H2 2018

Fallopian Tube Cancer – Pipeline by Celgene Corp, H2 2018

Fallopian Tube Cancer – Pipeline by Celldex Therapeutics Inc, H2 2018

Fallopian Tube Cancer – Pipeline by Celsion Corp, H2 2018

Fallopian Tube Cancer – Pipeline by Celyad SA, H2 2018

Fallopian Tube Cancer – Pipeline by Clovis Oncology Inc, H2 2018

Fallopian Tube Cancer – Pipeline by Corcept Therapeutics Inc, H2 2018

Fallopian Tube Cancer – Pipeline by Cotinga Pharmaceuticals Inc, H2 2018

Fallopian Tube Cancer – Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Fallopian Tube Cancer – Pipeline by Eisai Co Ltd, H2 2018

Fallopian Tube Cancer – Pipeline by Eli Lilly and Co, H2 2018

Fallopian Tube Cancer – Pipeline by EpiThany Inc, H2 2018

Fallopian Tube Cancer – Pipeline by Exelixis Inc, H2 2018

Fallopian Tube Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Fallopian Tube Cancer – Pipeline by Fate Therapeutics Inc, H2 2018

Fallopian Tube Cancer – Pipeline by Forty Seven Inc, H2 2018

Fallopian Tube Cancer – Pipeline by Gene Techno Science Co Ltd, H2 2018

Fallopian Tube Cancer – Pipeline by Genmab A/S, H2 2018

Fallopian Tube Cancer – Pipeline by GlaxoSmithKline Plc, H2 2018

Fallopian Tube Cancer – Pipeline by Gradalis Inc, H2 2018

List of Figures

List of Figures

Number of Products under Development for Fallopian Tube Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Figures

Number of Products under Development for Fallopian Tube Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports